logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Asthma Targeted Biological Therapies 1st Edition Girolamo Pelaia

  • SKU: BELL-5736730
Asthma Targeted Biological Therapies 1st Edition Girolamo Pelaia
$ 31.00 $ 45.00 (-31%)

4.4

72 reviews

Asthma Targeted Biological Therapies 1st Edition Girolamo Pelaia instant download after payment.

Publisher: Springer International Publishing
File Extension: PDF
File size: 2.42 MB
Pages: 99
Author: Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli (auth.)
ISBN: 9783319460055, 9783319460079, 3319460056, 3319460072
Language: English
Year: 2017
Edition: 1

Product desciption

Asthma Targeted Biological Therapies 1st Edition Girolamo Pelaia by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli (auth.) 9783319460055, 9783319460079, 3319460056, 3319460072 instant download after payment.

This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.

Related Products